Trial Profile
Costs and Outcome Among Patients With Chronic Myelogenous Leukemia (CML) Receiving Dasatinib or Nilotinib as First or Second Line Therapy in a Commercial and Medicare Population
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Mar 2015
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Nilotinib
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 19 Feb 2015 New trial record